Abstract

BackgroundTraditionally, final follicular maturation is triggered by a single bolus of human chorionic gonadotropin (hCG). This acts as a surrogate to the naturally occurring luteinizing hormone (LH) surge to induce luteinization of the granulosa cells, resumption of meiosis and final oocyte maturation. More recently, a bolus of gonadotropin-releasing hormone (GnRH) agonist in combination with hCG (dual trigger) has been suggested as an alternative regimen to achieve final follicular maturation.MethodsThis study was a systematic review and meta-analysis of randomized trials evaluating the effect of dual trigger versus hCG trigger for follicular maturation on pregnancy outcomes in women undergoing in vitro fertilization (IVF). The primary outcome was the live birth rate (LBR) per started cycle.ResultsA total of 1048 participants were included in the analysis, with 519 in the dual trigger group and 529 in the hCG trigger group. Dual trigger treatment was associated with a significantly higher LBR per started cycle compared with the hCG trigger treatment (risk ratio (RR) = 1.37 [1.07, 1.76], I2 = 0%, moderate evidence). There was a trend towards an increase in both ongoing pregnancy rate (RR = 1.34 [0.96, 1.89], I2 = 0%, low evidence) and implantation rate (RR = 1.31 [0.90, 1.91], I2 = 76%, low evidence) with dual trigger treatment compared with hCG trigger treatment. Dual trigger treatment was associated with a significant increase in clinical pregnancy rate (RR = 1.29 [1.10, 1.52], I2 = 13%, low evidence), number of oocytes collected (mean difference (MD) = 1.52 [0.59, 2.46), I2 = 53%, low evidence), number of mature oocytes collected (MD = 1.01 [0.43, 1.58], I2 = 18%, low evidence), number of fertilized oocytes (MD = 0.73 [0.16, 1.30], I2 = 7%, low evidence) and significantly more usable embryos (MD = 0.90 [0.42, 1.38], I2 = 0%, low evidence).ConclusionDual trigger treatment with GnRH agonist and HCG is associated with an increased live birth rate compared with conventional hCG trigger.Trial registrationCRD42020204452.

Highlights

  • In the conventional controlled ovarian stimulation (COS) regimen, final follicular maturation is triggered by a single bolus of human chorionic gonadotropin which acts as a surrogate to the naturally occurring luteinizing hormone (LH) surge to induce luteinization of the granulosa cells, resumption of meiosis and final oocyte maturation [3]

  • A total of 1048 participants were included in the analysis, with 519 in the dual trigger group and 529 in the human chorionic gonadotropin (hCG) trigger group

  • The dose of gonadotropin-releasing hormone (GnRH) agonist varied from 0.1 mg to 1 mg and the dose of hCG was the same with the control group in all studies except Mahajan (2016), which used 5000 IU hCG in the intervention group and 10,000 IU in the control group

Read more

Summary

Introduction

Final follicular maturation is triggered by a single bolus of human chorionic gonadotropin (hCG). This acts as a surrogate to the naturally occurring luteinizing hormone (LH) surge to induce luteinization of the granulosa cells, resumption of meiosis and final oocyte maturation. A bolus of gonadotropin-releasing hormone (GnRH) agonist in combination with hCG (dual trigger) has been suggested as an alternative regimen to achieve final follicular maturation. In the conventional controlled ovarian stimulation (COS) regimen, final follicular maturation is triggered by a single bolus of human chorionic gonadotropin (hCG) which acts as a surrogate to the naturally occurring LH surge to induce luteinization of the granulosa cells, resumption of meiosis and final oocyte maturation [3]. The use of dual trigger reduces the required dose of hCG, which is more applicable in women with risk factors for ovarian hyperstimulation syndrome [7, 8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call